Status:

COMPLETED

Optimal Dosage of Acetazolamide for OSA Treatment

Lead Sponsor:

University Hospital, Antwerp

Conditions:

Obstructive Sleep Apnea

Eligibility:

All Genders

18-79 years

Phase:

PHASE4

Brief Summary

Acetazolamide, a carbonic anhydrase inhibitor, has received some attention as potential treatment for obstructive sleep apnea (OSA). It produces a metabolic acidosis by excreting bicarbonate, thereby ...

Detailed Description

In this double-blind, parallel-group, controlled trial, eligible patients will be randomized into one of the following treatment arms: (1) placebo, (2) 250 mg of acetazolamide, or (3) 500 mg of acetaz...

Eligibility Criteria

Inclusion

  • AHI between 15 and 65 events/hour
  • BMI \< 35 kg/m²

Exclusion

  • Craniofacial anomalies
  • Central sleep apnea (defined as central AHI \> 25% of total AHI)
  • Contra-indications related to acetazolamide treatment
  • Hypersensitivity to sulphonamides or acetazolamide
  • Renal impairment, electrolyte imbalances, and/or adrenocortical insufficiency
  • Clinically significant metabolic, hepatic, and/or hematological disease
  • Chronic obstructive pulmonary disease
  • Closed-angle glaucoma
  • Conditions likely to affect OSA physiology: neuromuscular disease or other major neurological disorders, heart failure, or any other unstable major medical condition.
  • Intake of drugs that substantially stimulate or depress respiration, including benzodiazepines, opioids, theophylline, and pseudoephedrine
  • Inadequately treated sleep disorders other than OSA that would confound functional sleep assessment
  • Inability of the patient to understand and/or comply to the study procedures
  • Active psychiatric disease (psychotic illness, major depression, anxiety attacks, alcohol or drug abuse)
  • Pregnancy

Key Trial Info

Start Date :

April 20 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 5 2024

Estimated Enrollment :

91 Patients enrolled

Trial Details

Trial ID

NCT04726982

Start Date

April 20 2021

End Date

May 5 2024

Last Update

September 24 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Antwerp University Hospital

Edegem, Antwerp, Belgium, 2650

Optimal Dosage of Acetazolamide for OSA Treatment | DecenTrialz